Raymond James Financial upgraded Profound Medical stock to strong-buy, with MarketBeat providing consensus ratings.
1 report, 1 independent
Updated Oct 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial upgraded Profound Medical stock to strong-buy, with MarketBeat providing consensus ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Raymond James Financial
American Investment Bank and Financial Services Firm
Related events
- Analyst coverage for Septerna, including a new outperform rating from Raymond James Financial and coverage assumption by Truist Financial, reported via MarketBeat.
- Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.
- Citigroup reiterated a market perform rating, Bank of America restated an underperform rating, and Raymond James Financial started coverage for Omega Healthcare Investors, Inc.